MedTrace Logo

Nasal Decongestion and Obstructive Sleep Apnea

NCT00630474 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2009-12-23

No results posted yet for this study

Summary

Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.

Conditions

  • Obstructive Sleep Apnea Syndrome
  • Rhinitis

Interventions

DRUG

xylometazoline

xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Konrad E Bloch, MD · University Hospital, Zürich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2005-04-30
Completion
2005-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00630474 on ClinicalTrials.gov